Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04106414 · ClinicalTrials.gov registry record · Phase 2
Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment
A Phase 2 study of Endometrial Adenocarcinoma and Endometrial Carcinosarcoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 7
- Study locations
NCT04106414: Active Phase 2 study of Endometrial Adenocarcinoma and Endometrial Carcinosarcoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04106414 is a Phase 2 study of Endometrial Adenocarcinoma and Endometrial Carcinosarcoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 24 participants, below the 338-participant average among 13 other Endometrial Adenocarcinoma trials with a reported enrollment target (93% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04106414, a Phase 2 study of Endometrial Adenocarcinoma and Endometrial Carcinosarcoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study will compare the effects of treatment with nivolumab alone versus those of nivolumab plus the experimental drug BMS-986205. Adding BMS-986208 to nivolumab could shrink the cancer or prevent it from returning, but it could also cause side effects.
Primary Outcome
is measured by the best overall response rate as determined by RECIST 1.1.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG BMS- 986205
Study Locations (7)
New York
- Memorial Sloan Kettering Cancer Center @ Suffolk - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2019-09-24 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
What the registry record for NCT04106414 still lists
NCT04106414 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 338-participant average among 13 other Endometrial Adenocarcinoma trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Endometrial Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT04106414 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT04106414 about?
NCT04106414 is a clinical study titled "Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment". This study will compare the effects of treatment with nivolumab alone versus those of nivolumab plus the experimental drug BMS-986205. Adding BMS-986208 to nivolumab could shrink the cancer or prevent it from returning, but it could also cause side effects.
What is the current status of trial NCT04106414?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2019-09-24. Estimated completion is 2026-09.
What conditions does trial NCT04106414 study?
This clinical trial studies the following conditions: Endometrial Adenocarcinoma, Endometrial Carcinosarcoma.
What interventions are being tested in trial NCT04106414?
The interventions under investigation include: Nivolumab (DRUG), BMS- 986205 (DRUG).
Who is sponsoring clinical trial NCT04106414?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04106414 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04106414's enrollment target sits among peer trials
24 14th of 13 the lowest of 13 other Endometrial Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
RECRUITING · Phase 2
-
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
RECRUITING · Phase 2
-
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
ACTIVE NOT RECRUITING · Phase 2
-
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
COMPLETED · Phase 2
-
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI